Wednesday, July 16, 2025
HomeStocksQ3 results today: Ultratech, Adani Green among 59 companies to announce earnings...

Q3 results today: Ultratech, Adani Green among 59 companies to announce earnings on Thursday

-

[ad_1]

The third quarter earnings season is underway and about 59 companies will announce their results on Thursday. Key results to watch out for include Ultratech Cement, Adani Green, Dr Reddy’s, Mankind Pharma and HPCL.

Apart from the above, companies like ZEE, Cyient, Greaves Cotton, IEX, LKP Securities, Mphasis, Nippon Life AMC, Senores Pharma, Sona BLW Precision and a few others will also declare their quarter results.

Also Read : Catch all Q3 Results 2025 Live Updates Here

Ultratech Cement Q3 expectations

Cement major Ultratech is likely to see a decline in its profitability in the quarter ended December 2024, while the topline may rise marginally.

Revenue from operations during the third quarter could rise just 1% year-on-year (YoY), according to an average estimate of four brokerages. Profit after tax (PAT) may decline 29% YoY.

EBITDA for the quarter is estimated to decline 14% YoY and operating margins may contract 3.1 pp YoY to 16%.Ultratech is seeing pricing pressure from peer group despite having strong branding and market presence. Analysts also expect lower realizations during the quarter mainly on account of weak realization in white cement and clinker sale.Read more: Catch all Stallion India Share Price Live Updates Here.

Dr Reddy’s Q3 expectations

Pharma major Dr Reddy’s is expected to report double-digit growth in both bottomline and topline, led by stable sales in the US and growth in the organic business.

Net profit for the quarter is seen rising 10% year-on-year (YoY), according to an average estimate of four brokerages, while revenues are likely to increase 13% YoY.

Analysts estimate US sales to be stable YoY at $405-427 million, led by limited volume offtake in the differentiated portfolio.

Key factors to watch out for include update on the potential approval in the US over the next 12-18 million, denosumab launch in EU, effect of licenses and partnerships formed in recent years.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

[ad_2]

Source link

LATEST POSTS

Ceritafilm Explores the Heart of Every Movie Through Story Reviews

Introducing ceritafilm: Where Movies Meet Meaningful Stories In a world flooded with movie ratings, short reviews, and spoiler-filled discussions, https://ceritafilm.com stands out by offering something truly...

How to Standardise Laptop Setup for Staff: Creating Consistent Configurations

In today’s fast-paced business environment, ensuring that every employee’s laptop is set up consistently is more important than ever. A standardised laptop setup helps streamline...

Turn Health into Wealth with LifeWave X39

In today’s world, people are searching for two things more than ever:✅ Better health✅ Financial freedom With LifeWave X39, you don’t have to choose — you...

Soft Play Bus Essex with Squeeze Rollers & Dizzy Discs – A Fun-Filled Mobile Adventure

In today’s world of children’s entertainment, finding activities that combine physical play with safety and creativity can be a challenge. The Soft Play Bus Essex offers a...

Most Popular

spot_img